ArticleMolecular and cellular biochemistry2014
Novel quercetin derivatives in treatment of peroxynitrite-oxidized SERCA1.
Article in Molecular and cellular biochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of the Lipid Peroxidation Product 4-Hydroxynonenal on Neuroinflammation in Microglial Cells: Protective Role of Quercetin and Monochloropivaloylquercetin.Turkish journal of pharmaceutical sciences · 2019Article
- Effect of quercetin glucosides fromOncology letters · 2018Article
- Rutin stimulates sarcoplasmic reticulum Ca(2+)-ATPase activity (SERCA1) and protects SERCA1 from peroxynitrite mediated injury.Molecular and cellular biochemistry · 2015Article
- Quercetin ameliorates tunicamycin-induced endoplasmic reticulum stress in endothelial cells.Cell proliferation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarco/endoplasmic reticulum calcium ATP-ase (SERCA) is regulated by low concentrations of peroxynitrite and inhibited by high levels, as indicated in human diseases. We studied quercetin (Q) and its novel derivatives monochloropivaloylquercetin (MPQ) and chloronaphthoquinonequercetin (CHQ) as agents with expected preventive properties against peroxynitrite-induced SERCA impairment. Q and MPQ protected the SERCA1 against peroxynitrite induced activity decrease, while CHQ potentiated the inhibitory effect of peroxynitrite. Quercetin derivatives were found to be weaker antioxidants compared with Q, as indicated by their ability to scavenge peroxynitrite and prevent of SERCA1 carbonylation, both decreasing in the order (Q > MPQ > CHQ). Quantum-chemical values of theoretical parameter E HOMO also indicated lower antioxidant capacities for MPQ and CHQ. Prooxidant properties estimated by calculations of frontier molecular orbitals (E LUMO) correlated with experimentally determined SH-group decrease induced by the compounds studied. Both methods showed a decrease of prooxidant properties as follows: CHQ > MPQ > Q. In addition, experimentally measured half-wave potentials indicated stronger prooxidant properties of quercetin derivatives as compared to Q. More expressive alterations of conformation in the transmembrane region of SERCA1 induced by quercetin derivatives, as compared with Q, may at least partially correlate with their higher lipophilicities. The protective effects of Q and MPQ on different isoforms of SERCA activity may be useful in prevention and treatment of inflammation or muscle diseases. The inhibitory effect of CHQ on SERCA isoforms may be beneficial in therapeutic approaches aimed at anti-tumor treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.